The Simple Metric That Could Save Stimulant Use Disorder Treatment

Imagine trying to learn a new language. If the only definition of success is speaking like a native speaker on day one, everyone fails. But if success means ordering a coffee, suddenly we see progress.

For decades, clinical trials evaluating stimulant use disorder treatment have used an all-or-nothing rule: complete, unbroken abstinence. If a patient slips up even once, the trial counts it as a total failure. This rigid standard makes it incredibly difficult to identify medications that actually help people manage their addiction in the real world.

Redefining Success in Stimulant Use Disorder Treatment

Researchers conducted a meta-analysis of 12 clinical trials involving 2,000 participants recovering from cocaine or methamphetamine dependence. They analysed whether nine candidate medications, such as topiramate, bupropion, and cabergoline, helped patients transition from high-frequency use (five or more days a month) to low-frequency use (one to four days) or complete abstinence.

While the pooled active drugs did not outperform placebos overall, looking at individual drugs changed the picture. The medication cabergoline significantly increased the rates of reduced cocaine use compared to a placebo, offering a clear signal of efficacy.

A Realistic Metric for Recovery

This shift in focus suggests that tracking reduced drug use, rather than absolute abstinence, could identify helpful therapies that researchers previously dismissed.

• Measuring harm reduction captures clinical progress that strict urine tests miss.
• Cabergoline may offer a targeted option for cocaine reduction.
• Future trials could organise their metrics around realistic patient health outcomes.